Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 116 participants.
Also called NCT07118449
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 116 participants
- Sponsor
- XyloCor Therapeutics, Inc.
- Registry
-
NCT07118449 -
2025-521325-33-00
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07118449. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-27 (anticipated); primary completion 2026-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG
- Acronym
- EXACT-CABG
- Intervention (Drug)
- XC001
- Intervention (Drug)
- A195/placebo
- Lead sponsor
- XyloCor Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct07118449- Content hash
76c96f2563d8476bafcd22c9972de35345c8e71fffc71d4337cf659a2f0adc6b